• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素受体状态可预测卵巢癌脑转移的发生。

Androgen receptor status predicts development of brain metastases in ovarian cancers.

作者信息

Mittica Gloria, Senetta Rebecca, Scotto Giulia, Aglietta Massimo, Maggiorotto Furio, Ghisoni Eleonora, Genta Sofia, Boldorini Renzo, Manini Claudia, Morra Isabella, Buosi Roberta, Sapino Anna, Cassoni Paola, Valabrega Giorgio

机构信息

Department of Oncology, University of Turin, Turin, Italy.

Division of Medical Oncology-1, Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy.

出版信息

Oncotarget. 2017 Jun 20;8(25):41143-41153. doi: 10.18632/oncotarget.17068.

DOI:10.18632/oncotarget.17068
PMID:28467804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5522232/
Abstract

Brain metastases are uncommon localizations in epithelial ovarian cancer (EOC), their reported incidence is increasing and no predictive biomarkers have been identified yet. Goals of this study were: i) to define a possible association between Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify differences in ER, PR, AR and HER2 protein expression from primary EOC and its matched resected brain metastasis. A retrospective series of 11 EOC with matched brain metastasis surgically removed was collected. For comparison, a "Control dataset" of 22 patients, without evidence of brain involvement after an adequate follow up was matched. ER, PR, AR and HER2 status were analyzed by means of immunohistochemistry forCases (both primary and metastatic lesions) and Controls.Univariate analysis showed that AR status was significantly associated with brain localization, both considered as discrete variable (cut-off: 10%, p=0.013) and as continuous one (p=0.035). Multivariate analysis confirmed this trend (p=0.053). When considered as continuous variables, ER and AR showed greater expression in primary tumors in comparison with brain metastases (p=0.013 and p=0.032, respectively).In our series, AR predicts brain involvement, with a 9.5 times higher propensity for AR-negative EOC. Moreover, brain dissemination is probably the result of progressive dedifferentiation of primary tumor, shown by reduction of ER and AR expression in metastases. Further studies are required, in order to anticipate and improve multimodal treatment of brain metastases.

摘要

脑转移在上皮性卵巢癌(EOC)中是不常见的转移部位,其报告发病率正在上升,且尚未发现预测性生物标志物。本研究的目的是:i)确定雌激素受体(ER)、孕激素受体(PR)、雄激素受体(AR)、人表皮生长因子受体2(HER2)与EOC患者脑转移之间的可能关联,以及ii)确定原发性EOC及其匹配的切除脑转移瘤中ER、PR、AR和HER2蛋白表达的差异。收集了11例经手术切除且伴有匹配脑转移瘤的EOC回顾性病例系列。为作比较,匹配了一个由22例患者组成的“对照数据集”,这些患者在充分随访后无脑转移证据。通过免疫组织化学分析病例组(原发性和转移性病变)和对照组的ER、PR、AR和HER2状态。单因素分析表明,AR状态与脑转移显著相关,无论是作为离散变量(临界值:10%,p=0.013)还是作为连续变量(p=0.035)。多因素分析证实了这一趋势(p=0.053)。当作为连续变量考虑时,与脑转移瘤相比,ER和AR在原发性肿瘤中的表达更高(分别为p=0.013和p=0.032)。在我们的病例系列中,AR可预测脑转移,AR阴性的EOC发生脑转移的倾向高9.5倍。此外,脑转移可能是原发性肿瘤进行性去分化的结果,转移瘤中ER和AR表达的降低表明了这一点。需要进一步研究,以预测和改善脑转移的多模式治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91e0/5522232/5e5cb01adf7a/oncotarget-08-41143-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91e0/5522232/7e2e1d240bd7/oncotarget-08-41143-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91e0/5522232/5e5cb01adf7a/oncotarget-08-41143-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91e0/5522232/7e2e1d240bd7/oncotarget-08-41143-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/91e0/5522232/5e5cb01adf7a/oncotarget-08-41143-g002.jpg

相似文献

1
Androgen receptor status predicts development of brain metastases in ovarian cancers.雄激素受体状态可预测卵巢癌脑转移的发生。
Oncotarget. 2017 Jun 20;8(25):41143-41153. doi: 10.18632/oncotarget.17068.
2
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers.验证雄激素受体缺失是否为卵巢癌脑转移发展的风险因素。
J Ovarian Res. 2020 May 4;13(1):53. doi: 10.1186/s13048-020-00655-2.
3
Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the "triple-negative" tumor status to disease-free and overall survival of women with epithelial ovarian cancer.分析免疫可检测的HER2、类固醇受体以及“三阴性”肿瘤状态对上皮性卵巢癌女性无病生存期和总生存期的影响。
Acta Histochem. 2014 Apr;116(3):440-7. doi: 10.1016/j.acthis.2013.09.010. Epub 2013 Nov 12.
4
Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy.雄激素受体表达在初始手术切除的乳腺癌转移中通常得到维持,但在尸检时发现的终末期转移中常丢失。
Hum Pathol. 2012 Jul;43(7):1003-11. doi: 10.1016/j.humpath.2011.08.007. Epub 2011 Dec 10.
5
Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?激素受体、HER2/NEU和表皮生长因子受体在卵巢癌中的表达——这是一种预后表型吗?
Asian Pac J Cancer Prev. 2014;15(22):9739-45. doi: 10.7314/apjcp.2014.15.22.9739.
6
Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.雄激素受体和转移相关蛋白-1在雌激素受体阴性/人表皮生长因子受体2阳性乳腺癌中经常表达。
Virchows Arch. 2016 Jun;468(6):687-96. doi: 10.1007/s00428-016-1930-0. Epub 2016 Mar 30.
7
Expression of androgen receptor and its phosphorylated forms in breast cancer progression.雄激素受体及其磷酸化形式在乳腺癌进展中的表达。
Cancer. 2013 Jul 15;119(14):2532-40. doi: 10.1002/cncr.28092. Epub 2013 Apr 19.
8
Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.转移性乳腺癌患者原发肿瘤、转移灶及循环肿瘤细胞中HER2、雌激素和孕激素受体表达谱的比较。
BMC Cancer. 2016 Jul 25;16:522. doi: 10.1186/s12885-016-2587-4.
9
Does androgen receptor have a prognostic role in patients with estrogen/progesterone-negative and c-erbB-2-positive breast cancer?雄激素受体在雌激素/孕激素阴性且c-erbB-2阳性的乳腺癌患者中是否具有预后作用?
Am Surg. 2012 Sep;78(9):992-9.
10
Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer.雄激素受体表达是高级别浆液性上皮性卵巢癌雄激素敏感性的生物学标志物。
Gynecol Oncol. 2012 Jan;124(1):142-7. doi: 10.1016/j.ygyno.2011.09.004. Epub 2011 Oct 15.

引用本文的文献

1
Relationship between PIWIL1 gene polymorphisms and epithelial ovarian cancer susceptibility among southern Chinese woman: a three-center case-control study.PIWIL1 基因多态性与中国南方女性上皮性卵巢癌易感性的关系:一项三中心病例对照研究。
BMC Cancer. 2023 Nov 27;23(1):1149. doi: 10.1186/s12885-023-11651-2.
2
Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options.激素受体与上皮性卵巢癌:生物学及治疗选择的最新进展
Biomedicines. 2023 Aug 1;11(8):2157. doi: 10.3390/biomedicines11082157.
3
Pathway-level mutation analysis in primary high-grade serous ovarian cancer and matched brain metastases.

本文引用的文献

1
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19).上皮性卵巢癌患者的脑转移:临床病理及预后因素。一项来自MITO研究组(MITO 19)的多中心回顾性分析。
Gynecol Oncol. 2016 Dec;143(3):532-538. doi: 10.1016/j.ygyno.2016.09.025. Epub 2016 Oct 5.
2
Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations.浆液性卵巢癌中的激素受体:预后、发病机制及治疗考量
Clin Med Insights Oncol. 2016 Mar 29;10:17-25. doi: 10.4137/CMO.S32813. eCollection 2016.
3
Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.
原发高级别浆液性卵巢癌及其配对脑转移灶的通路水平突变分析。
Sci Rep. 2022 Nov 29;12(1):20537. doi: 10.1038/s41598-022-23788-4.
4
Molecular Regulation of Androgen Receptors in Major Female Reproductive System Cancers.雄激素受体在女性主要生殖系统癌症中的分子调控。
Int J Mol Sci. 2022 Jul 8;23(14):7556. doi: 10.3390/ijms23147556.
5
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer.上皮性卵巢癌的中枢神经系统受累的生物标志物。
Cells. 2021 Dec 3;10(12):3408. doi: 10.3390/cells10123408.
6
Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.拉沙病毒-水泡性口炎病毒嵌合病毒通过直接溶瘤作用和引发抗肿瘤反应靶向并摧毁人类和小鼠卵巢癌细胞。
Virology. 2021 Mar;555:44-55. doi: 10.1016/j.virol.2020.10.009. Epub 2020 Nov 12.
7
Metastatic epithelial ovarian cancer to Meckel's cave with leptomeningeal spread at time of diagnosis.诊断时发生转移至梅克尔腔并伴有软脑膜播散的上皮性卵巢癌。
Gynecol Oncol Rep. 2020 Sep 11;34:100641. doi: 10.1016/j.gore.2020.100641. eCollection 2020 Nov.
8
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis.卵巢癌脑转移:诊断、治疗及预后的当前证据
Cancers (Basel). 2020 Aug 4;12(8):2156. doi: 10.3390/cancers12082156.
9
Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers.验证雄激素受体缺失是否为卵巢癌脑转移发展的风险因素。
J Ovarian Res. 2020 May 4;13(1):53. doi: 10.1186/s13048-020-00655-2.
KIF2A和HER2-Neu过表达在上皮性卵巢癌患者中的预后价值
Medicine (Baltimore). 2016 Feb;95(8):e2803. doi: 10.1097/MD.0000000000002803.
4
Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival.雄激素受体由健康的绝经后子宫内膜上皮获得,其在子宫内膜癌中的随后丧失与较差的生存率相关。
Br J Cancer. 2016 Mar 15;114(6):688-96. doi: 10.1038/bjc.2016.16. Epub 2016 Mar 1.
5
Cancer statistics, 2016.癌症统计数据,2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
6
Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.性类固醇激素受体表达影响卵巢癌患者的生存。
Transl Oncol. 2015 Oct;8(5):424-433. doi: 10.1016/j.tranon.2015.09.002.
7
Hormone receptors as a marker of poor survival in epithelial ovarian cancer.激素受体作为上皮性卵巢癌患者生存不良的标志物。
Gynecol Oncol. 2015 Sep;138(3):634-9. doi: 10.1016/j.ygyno.2015.06.032. Epub 2015 Jun 24.
8
Hormone receptor, HER2/NEU and EGFR expression in ovarian carcinoma--is here a prognostic phenotype?激素受体、HER2/NEU和表皮生长因子受体在卵巢癌中的表达——这是一种预后表型吗?
Asian Pac J Cancer Prev. 2014;15(22):9739-45. doi: 10.7314/apjcp.2014.15.22.9739.
9
Clinical significance of hormonal receptor status of malignant ovarian tumors.恶性卵巢肿瘤激素受体状态的临床意义。
Exp Oncol. 2014 Jun;36(2):125-33.
10
Brain metastasis from ovarian cancer: a systematic review.卵巢癌脑转移:一项系统综述
J Neurooncol. 2014 Aug;119(1):1-6. doi: 10.1007/s11060-014-1447-9. Epub 2014 May 1.